Bank of Montreal Can raised its stake in DexCom, Inc. (NASDAQ:DXCM) by 69.2% during the second quarter, Holdings Channel reports. The fund owned 31,403 shares of the medical device company’s stock after buying an additional 12,847 shares during the period. Bank of Montreal Can’s holdings in DexCom were worth $2,296,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. increased its position in DexCom by 5,000.4% in the first quarter. BlackRock Inc. now owns 4,160,862 shares of the medical device company’s stock valued at $352,550,000 after buying an additional 4,079,283 shares during the last quarter. Bank of New York Mellon Corp increased its position in DexCom by 304.3% in the first quarter. Bank of New York Mellon Corp now owns 2,546,729 shares of the medical device company’s stock valued at $215,785,000 after buying an additional 1,916,759 shares during the last quarter. FMR LLC increased its position in DexCom by 9.1% in the first quarter. FMR LLC now owns 9,845,408 shares of the medical device company’s stock valued at $834,201,000 after buying an additional 823,406 shares during the last quarter. Janus Capital Management LLC increased its position in DexCom by 12.2% in the first quarter. Janus Capital Management LLC now owns 4,001,971 shares of the medical device company’s stock valued at $339,083,000 after buying an additional 436,162 shares during the last quarter. Finally, Morgan Stanley increased its position in DexCom by 18.0% in the first quarter. Morgan Stanley now owns 2,092,962 shares of the medical device company’s stock valued at $177,336,000 after buying an additional 319,631 shares during the last quarter.

Shares of DexCom, Inc. (DXCM) traded down 1.00% during mid-day trading on Friday, reaching $69.10. The company had a trading volume of 440,692 shares. The company’s market capitalization is $5.98 billion. The stock’s 50-day moving average price is $71.38 and its 200 day moving average price is $75.25. DexCom, Inc. has a 1-year low of $57.68 and a 1-year high of $96.38.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.07. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The company had revenue of $170.60 million for the quarter, compared to analyst estimates of $166.54 million. During the same quarter in the previous year, the company posted ($0.24) earnings per share. The firm’s revenue for the quarter was up 24.3% compared to the same quarter last year. Equities analysts expect that DexCom, Inc. will post ($0.77) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.watchlistnews.com/dexcom-inc-nasdaqdxcm-stake-boosted-by-bank-of-montreal-can/1472605.html.

Several research analysts have weighed in on DXCM shares. Cowen and Company restated an “outperform” rating and issued a $90.00 price target on shares of DexCom in a research note on Tuesday, April 18th. BidaskClub upgraded DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, June 21st. BTIG Research downgraded DexCom from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 3rd. Jefferies Group LLC dropped their price target on DexCom to $91.00 and set a “buy” rating for the company in a research note on Tuesday, May 9th. Finally, William Blair restated an “outperform” rating on shares of DexCom in a research note on Thursday, April 27th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and fifteen have issued a buy rating to the company’s stock. DexCom currently has an average rating of “Buy” and a consensus target price of $87.00.

In other news, EVP Richard Doubleday sold 3,182 shares of the company’s stock in a transaction on Tuesday, May 23rd. The stock was sold at an average price of $68.29, for a total value of $217,298.78. Following the transaction, the executive vice president now owns 72,395 shares of the company’s stock, valued at approximately $4,943,854.55. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Kevin R. Sayer sold 8,649 shares of the company’s stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $68.39, for a total value of $591,505.11. Following the completion of the transaction, the chief executive officer now directly owns 347,329 shares in the company, valued at approximately $23,753,830.31. The disclosure for this sale can be found here. In the last ninety days, insiders sold 33,131 shares of company stock worth $2,318,443. Corporate insiders own 1.70% of the company’s stock.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.